Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Facilitated Immunoglobulin Administration Registry and Outcomes Study

ID
Name
FIGARO
Description
Long-term observational study on the utilisation and outcomes of HyQvia (a product consisting of recombinant human hyaluronidase and a human normal immunoglobulin 10% solution) under everyday clinical practice conditions.
Trial arms
Trial start
2016-12-22
Estimated PCD
2021-11-30
Trial end
2021-11-30
Status
Completed
Treatment
HyQvia
Arms:
HyQvia
Other names:
Recombinant human hyaluronidase and normal immunoglobulin 10%
Size
156
Primary endpoint
Utilisation in terms of dose and dosing interval
up to 3 years
Eligibility criteria
Inclusion Criteria: * Patient has received/will receive at least 1 HyQvia infusion for PID or SID * Patient has an indication for chronic immunoglobulin treatment * Patient is likely available for long-term documentation * Patient provides informed consent for documentation Exclusion Criteria: * No explicit exclusion criteria apply.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 156, 'type': 'ACTUAL'}}
Updated at
2023-09-14

1 organization

1 product

2 indications

Organization
GWT-TUD
Product
HyQvia
Indication
Primary Immunodeficiency
Indication
Secondary Immune Deficiency